Evommune to Present EVO756 Data at EADV 2025 Congress
Evommune, Inc., a clinical stage biotechnology company dedicated to discovering and developing cutting-edge therapies for chronic inflammatory diseases, is set to make waves at the European Academy of Dermatology and Venereology (EADV) 2025 Congress. At this important event, the company will unveil comprehensive data from their Phase 2 trial of EVO756, providing hope for individuals coping with chronic inducible urticaria (CIndU).
The Significance of EVO756
EVO756 stands out as a powerful and highly selective oral small molecule that acts as an antagonist to the mas-related G-protein coupled receptor X2 (MRGPRX2). This innovative drug has the potential to revolutionize treatment methods by tackling the disease from multiple angles, aimed at delivering results for both mast cells and peripheral sensory neurons. Currently, EVO756 is also undergoing extensive Phase 2b trials targeting Chronic Spontaneous Urticaria and Atopic Dermatitis.
Details of the Upcoming Presentation
The eagerly awaited late-breaker oral presentation will feature the abstract titled "EVO756, an Oral MRGPRX2 Inhibitor, Demonstrates Robust Treatment Effect in Chronic Inducible Urticaria." Scheduled for September 19, the presentation will take place during the D3T01.3B session in the Paris Nord room, with significant insights expected from 2:30 to 2:45 pm CEST, which is 8:30 to 8:45 am EST.
Webcast Information
To ensure wider accessibility to their findings, Evommune plans to host a live webcast that will delve into the data presented at EADV. This event will be led by Dr. Edward (Ted) Lain, an experienced board-certified dermatologist and clinical investigator alongside the company’s management team. The webcast will be available on the Evommune website at the same time the press release and presentation go live, allowing for comprehensive community engagement.
Innovative Approach with EVO756
Evommune is fervently developing EVO756 as a first-in-class oral treatment targeting MRGPRX2 for chronic inflammatory conditions, notably Chronic Spontaneous Urticaria and Atopic Dermatitis. The pressing need for advanced therapies in these markets is evident due to the limitations faced by current treatment options. EVO756 promises improved efficacy and safety with user-friendly oral dosage, addressing the unmet medical needs of patients.
The Dual Mechanism Advantage
EVO756 is recognized for its unique dual mechanism approach, successfully modulating both mast cells and peripheral sensory neurons. This innovative strategy presents a compelling therapeutic option that could significantly mitigate inflammation and provide rapid relief from itchiness, often referred to as pruritus, common in chronic inflammatory scenarios.
About Evommune, Inc.
Evommune prides itself on being a pioneering clinical-stage biotechnology company that embarks on the journey to address chronic inflammatory diseases through innovative therapies. The core mission is to enhance the daily lives of patients while averting long-term issues associated with uncontrolled inflammation due to the shortcomings of existing treatments. Aiming for excellence, the company is making headway with a diverse portfolio of differentiated product candidates that tackle underlying causes of chronic inflammation.
Frequently Asked Questions
What is EVO756 targeting?
EVO756 targets the mas-related G-protein coupled receptor X2 (MRGPRX2), focusing on chronic inflammatory diseases such as chronic inducible urticaria.
When will the EVO756 data be presented?
The data will be presented on September 19 during the EADV 2025 Congress in Paris.
What is the significance of the presentation?
The presentation highlights the effectiveness of EVO756, showcasing its potential as a groundbreaking treatment option.
Who will lead the webcast?
The webcast will be led by Dr. Edward (Ted) Lain, along with Evommune's management team.
What is Evommune’s mission?
Evommune aims to develop innovative treatments that significantly improve the lives of patients dealing with chronic inflammatory conditions.
